KRMD
NEUTRAL
$4.21
Live
KORU Medical Systems, Inc. · NASDAQ
Target $6.8
(+61.5%)
$2.08
52W Range
$6.61
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$195.82M
P/E
N/A
ROE
-15.6%
Profit margin
-6.4%
Debt/Equity
0.21
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
KRMD presents a contradictory profile, characterized by a weak Piotroski F-Score of 2/9 which signals poor operational efficiency and financial health trends. However, this is offset by strong top-line growth of 23.3% and a robust gross margin of 62.26%, suggesting a scalable product. While the company is trending toward profitability with consistent earnings beats, it trades at a significant valuation premium with a Price-to-Book ratio of 11.44. The overall outlook is neutral as the growth potential is currently weighed down by weak fundamental health metrics and bearish short-term technicals.
Key Strengths
Strong gross margins (62.26%) indicating high product value
Consistent earnings beat track record (3/4 last 4 quarters)
Low leverage with a Debt/Equity ratio of 0.21
Healthy short-term liquidity (Current Ratio 2.44)
Strong YoY revenue growth of 23.30%
Key Risks
Very weak Piotroski F-Score (2/9) indicating fundamental instability
Excessive valuation premium (P/B 11.44)
Negative net profit and operating margins
Bearish short-term technical trend (0/100)
Small-cap volatility and lack of dividend support
AI Fair Value Estimate
Based on comprehensive analysis
$5.5
+30.6% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
38
Weak
30
75
60
25
0
AI Verdict
Speculative Growth
Key drivers: Revenue growth, Path to profitability, Poor F-Score, High P/B ratio
Confidence
80%
Value
30/100
No Graham Number available; stock trades at a significant premium to book value.
Positives
- Forward P/E is defined (49.53)
Watchpoints
- P/B of 11.44 is extremely high
- P/S of 4.76 is steep for the sector
Future
75/100
Growth rates are strong and earnings are trending toward the positive.
Positives
- 23.3% YoY revenue growth
- Positive EPS surprises (+143.33% avg)
- Strong analyst target price ($6.80)
Watchpoints
- Still operating at a net loss
Past
60/100
Strong annual performance but losing short-term momentum.
Positives
- 1Y price return of +84.7%
Watchpoints
- Recent 1-month trend is negative (-6.7%)
- Historical ROE is negative
Health
25/100
While liquidity is good, the F-Score indicates a failure in operational health and efficiency.
Positives
- Low Debt/Equity (0.21)
- Strong Current Ratio (2.44)
Watchpoints
- Piotroski F-Score of 2/9 is critically low
Dividend
0/100
Company is in a growth phase and does not distribute capital.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.21
Analyst Target
$6.8
Upside/Downside
+61.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for KRMD and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
KRMD
KORU Medical Systems, Inc.
Primary
|
+27.2% | +4.2% | +84.7% | -1.9% | -6.7% | -2.5% |
|
ADAG
Adagene Inc.
Peer
|
-81.2% | +188.8% | +109.6% | +84.4% | +33.2% | +45.4% |
|
ACB
Aurora Cannabis Inc.
Peer
|
-96.9% | -52.9% | -20.2% | -29.6% | -0.3% | -2.3% |
|
ARCT
Arcturus Therapeutics Holdings Inc.
Peer
|
-87.2% | -57.7% | -51.9% | -61.4% | -9.7% | -6.0% |
|
ANIK
Anika Therapeutics, Inc.
Peer
|
-62.2% | -47.2% | -6.6% | +63.8% | +38.5% | +0.6% |
KRM
KORU Medical Systems, Inc.
Primary
5Y
+27.2%
3Y
+4.2%
1Y
+84.7%
6M
-1.9%
1M
-6.7%
1W
-2.5%
ADA
Adagene Inc.
Peer
5Y
-81.2%
3Y
+188.8%
1Y
+109.6%
6M
+84.4%
1M
+33.2%
1W
+45.4%
ACB
Aurora Cannabis Inc.
Peer
5Y
-96.9%
3Y
-52.9%
1Y
-20.2%
6M
-29.6%
1M
-0.3%
1W
-2.3%
ARC
Arcturus Therapeutics Holdings Inc.
Peer
5Y
-87.2%
3Y
-57.7%
1Y
-51.9%
6M
-61.4%
1M
-9.7%
1W
-6.0%
ANI
Anika Therapeutics, Inc.
Peer
5Y
-62.2%
3Y
-47.2%
1Y
-6.6%
6M
+63.8%
1M
+38.5%
1W
+0.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
49.53
PEG Ratio
N/A
P/B Ratio
11.44
P/S Ratio
4.76
EV/Revenue
4.62
EV/EBITDA
-83.27
Market Cap
$195.82M
Profitability
Profit margins and return metrics
Profit Margin
-6.41%
Operating Margin
-5.02%
Gross Margin
62.26%
ROE
-15.58%
ROA
-6.71%
Growth
Revenue and earnings growth rates
Revenue Growth
+23.3%
Earnings Growth
N/A
Q/Q Revenue Growth
+23.27%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.21
Low debt
Current Ratio
2.44
Strong
Quick Ratio
1.88
Excellent
Cash/Share
$0.19
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
62.6%
Op. Margin
-5.0%
Net Margin
-4.5%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.65x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
61%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-03-12
$0.01
+180.0% surprise
2025-11-12
$N/A
+100.0% surprise
2025-08-06
$0.01
+150.0% surprise
Healthcare Sector Comparison
Comparing KRMD against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
Return on Equity (ROE)
-15.58%
This Stock
vs
-49.88%
Sector Avg
-68.8%
(Below Avg)
Profit Margin
-6.41%
This Stock
vs
-9.43%
Sector Avg
-32.0%
(Weaker)
Debt to Equity
0.21
This Stock
vs
3.74
Sector Avg
-94.5%
(Less Debt)
Revenue Growth
23.3%
This Stock
vs
80.78%
Sector Avg
-71.2%
(Slower)
Current Ratio
2.44
This Stock
vs
3.72
Sector Avg
-34.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
KRMD
KORU Medical Systems, Inc.
|
NEUTRAL | $195.82M | - | -15.6% | -6.4% | $4.21 | |
|
ADAG
Adagene Inc.
|
BULLISH | $194.65M | - | -63.3% | -% | $4.13 | Compare |
|
ACB
Aurora Cannabis Inc.
|
BEARISH | $194.51M | - | -15.5% | -22.5% | $3.43 | Compare |
|
ARCT
Arcturus Therapeutics Holdings Inc.
|
BEARISH | $189.87M | - | -28.9% | -80.2% | $6.68 | Compare |
|
ANIK
Anika Therapeutics, Inc.
|
BEARISH | $204.78M | - | -6.7% | -9.6% | $14.2 | Compare |
KRMD
KORU Medical...
NEUTRAL
Mkt Cap
$196M
P/E
-
ROE
-15.6%
Price
$4.21
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | FLETCHER R JOHN | Chairman of the Board | Stock Award | 5,208 | $22,499 |
| 2026-04-01 | CASCELLA ROBERT A | Director | Stock Award | 3,472 | $14,999 |
| 2026-04-01 | MATIN SHAHRIAR | Director | Stock Award | 3,472 | $14,999 |
| 2026-04-01 | WHOLIHAN EDWARD | Director | Stock Award | 3,472 | $14,999 |
| 2026-04-01 | FRENCH DONNA | Director | Stock Award | 3,472 | $14,999 |
| 2026-03-31 | MANKO JOSEPH M JR | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 3,472 | - |
| 2026-03-31 | MANKO JOSEPH M JR | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 3,472 | - |
| 2026-03-16 | THARBY LINDA M | Chief Executive Officer | Stock Award | 15,968 | - |
| 2026-03-16 | ADAMS THOMAS EDWARD | Chief Financial Officer | Stock Award | 5,404 | - |
| 2026-03-16 | PAZDAN CHRISTOPHER | Chief Operating Officer | Stock Award | 5,064 | - |
| 2026-01-02 | FLETCHER R JOHN | Chairman of the Board | Stock Award | 3,872 | $22,496 |
| 2026-01-02 | CASCELLA ROBERT A | Director | Stock Award | 2,581 | $14,996 |
| 2026-01-02 | MATIN SHAHRIAR | Director | Stock Award | 2,581 | $14,996 |
| 2026-01-02 | WHOLIHAN EDWARD | Director | Stock Award | 2,581 | $14,996 |
| 2026-01-02 | FRENCH DONNA | Director | Stock Award | 2,581 | $14,996 |
FLETCHER R JOHN
Chairman of the Board
2026-04-01
5,208 shares
·
$22,499
CASCELLA ROBERT A
Director
2026-04-01
3,472 shares
·
$14,999
MATIN SHAHRIAR
Director
2026-04-01
3,472 shares
·
$14,999
WHOLIHAN EDWARD
Director
2026-04-01
3,472 shares
·
$14,999
FRENCH DONNA
Director
2026-04-01
3,472 shares
·
$14,999
MANKO JOSEPH M JR
Director and Beneficial Owner of more than 10% of a Class of Security
2026-03-31
3,472 shares
MANKO JOSEPH M JR
Director and Beneficial Owner of more than 10% of a Class of Security
2026-03-31
3,472 shares
THARBY LINDA M
Chief Executive Officer
2026-03-16
15,968 shares
ADAMS THOMAS EDWARD
Chief Financial Officer
2026-03-16
5,404 shares
PAZDAN CHRISTOPHER
Chief Operating Officer
2026-03-16
5,064 shares
FLETCHER R JOHN
Chairman of the Board
2026-01-02
3,872 shares
·
$22,496
CASCELLA ROBERT A
Director
2026-01-02
2,581 shares
·
$14,996
MATIN SHAHRIAR
Director
2026-01-02
2,581 shares
·
$14,996
WHOLIHAN EDWARD
Director
2026-01-02
2,581 shares
·
$14,996
FRENCH DONNA
Director
2026-01-02
2,581 shares
·
$14,996
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
5 analysts
Canaccord Genuity
2026-03-13
Buy
Buy
B. Riley Securities
2026-03-13
Buy
Buy
Lake Street
2025-12-22
Buy
Buy
Canaccord Genuity
2025-12-17
Buy
Buy
Past News Coverage
Recent headlines mentioning KRMD from our newsroom.
Newest → oldest
No matching news yet.